a scientificity and feasibility evaluation of covid 19 clinical studies registered CORD-Papers-2021-10-25 (Version 1)

Title: A scientificity and feasibility evaluation of COVID-19 clinical studies registered in China
Abstract: BACKGROUND: An outbreak of novel coronavirus infection in Wuhan, China, in early 2020 has now developed into a worldwide pandemic Researchers in China and around the world have conducted many clinical studies on the scientific response to infectious diseases Here, we review and summarize the registration protocols for clinical research of the novel coronavirus disease (COVID-19) METHODS: We searched all the registered studies in all platforms under the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization (WHO) before March 11, 2020, screened the registration scheme for novel coronavirus, extracted the basic research information, research quality, feasibility information, and described the scientificity and feasibility of interventional research RESULTS: From January 23, 2020 to March 11, 2020, 379 clinical studies were registered, 260 were therapeutic studies among them, and 96 8% studies were conducted in China by Chinese researchers Some studies were registered 2 weeks just after the virus was identified, and up to 22 studies registered for one day The number of interventional studies was greater than observational studies (263 vs 116) Among the interventional studies, nearly 50% studies were funded, 87 7% were randomized, and 79 4% of the primary outcome indicators were objective However, the sample size of the studies ranged from 60 to 200, with the total sample size accounting for 40% of the confirmed infected population More than 60% studies might face the problem of insufficient sample size CONCLUSIONS: COVID-19 clinical study registration has been considerable, rapid, and high quality in study design However, the feasibility of these studies may still be problematic, especially in such as insufficient sample size, poor coordination among multidisciplinary teams, and weak quality control in the research process
Published: 2020
Journal: Annals of translational medicine
Author Name: Tao, L
Author link: https://covid19-data.nist.gov/pid/rest/local/author/tao_l
Author Name: Zhang, H
Author link: https://covid19-data.nist.gov/pid/rest/local/author/zhang_h
Author Name: Zhuo, L
Author link: https://covid19-data.nist.gov/pid/rest/local/author/zhuo_l
Author Name: Liu, Y
Author link: https://covid19-data.nist.gov/pid/rest/local/author/liu_y
Author Name: Qiao, R
Author link: https://covid19-data.nist.gov/pid/rest/local/author/qiao_r
Author Name: Zhao, Y
Author link: https://covid19-data.nist.gov/pid/rest/local/author/zhao_y
Author Name: Zhan, S
Author link: https://covid19-data.nist.gov/pid/rest/local/author/zhan_s
license: unk
license_url: [unknown license]
source_x: WHO
source_x_url: https://www.who.int/
who_covidence_id: #832025
has_full_text: FALSE
G_ID: a_scientificity_and_feasibility_evaluation_of_covid_19_clinical_studies_registered
S2 ID: 221126417